In late 2003 a 47-h-old neonate with a 9-h history of poor feeding and lethargy was airlifted from a community hospital in rural northern California to an acute-care tertiary facility in San Francisco, California, where the admitting diagnosis was acute hypotonia and respiratory failure. An inborn error of metabolism was suspected because the urine had an unusually sweet smell, which prompted suspicion of maple syrup urine disease. As a result, the patient underwent three consecutive daily courses of hemodialysis. The day after the third course, she had intermittent movement of her distal extremities but otherwise remained mostly hypotonic. The possibility of infant botulism was initially dismissed because of the patient's young age, fulminant onset of illness, and the quick recovery of her slight distal extremity control.
By hospital day 12 all metabolic test results were normal, thereby leading the attending neurologists to consider the possibility of infant botulism. A stool specimen submitted to our laboratory was emulsified and extracted in gelatin phosphate diluent and centrifuged. The extract was injected into pairs of Swiss-Webster mice in accord with the standard mouse neutralization bioassay for botulinum toxin detection (Table 1 ) (5). All relevant institutional policies and federal guidelines for the ethical use of laboratory animals were followed. The stool pellet was inoculated into two chopped-meat-glucose-starch broth tubes and onto 4% egg yolk agar, botulinum selective medium (16) , and 5% Schaedler sheep blood agar. One broth tube was heat-shocked at 70°C for 15 min. All media were incubated at 35°C in an anaerobe chamber (5) .
The bioassay of the stool extract identified a heat-labile toxin that was neutralized only by type F monovalent botulinum antitoxin ( Table 1 ). The directly inoculated stool culture plates revealed heavy growth of lecithinase-positive colonies in almost pure culture on egg yolk agar and slightly beta-hemolytic colonies on sheep blood agar after 24 h of incubation. No growth was observed on botulinum selective medium at 72 h. Nonproteolytic growth was evident at 24 h in both broth culture tubes. Filtrate from a pure culture of the lecithinasepositive organism, like the stool extract, tested positive for botulinum toxin type F. Test results from additional subsequent stool specimens confirmed the finding (Table 1) . Biochemical characterization and 16S rRNA sequencing, together with the culture and bioassay results, identified the organism as Clostridium baratii type F. The patient received supportive care but was not treated intravenously with botulism immune globulin (human) (commercially known as BabyBIG) because of the delayed referral. Although initially severely paralyzed, the patient quickly regained muscle strength and was released from the hospital on day 19 of illness. The three episodes of hemodialysis for suspected maple syrup urine disease early in the course of illness may have aided in the rapid recovery. Intestinal colonization by C. baratii lasted more than 3, but less than 5, weeks (Table 1) . C. baratii differs from the ubiquitous C. botulinum in that an environmental source of toxigenic C. baratii has not been identified, so an extensive investigation to identify a possible environmental reservoir of this organism was undertaken. An epidemiological interview was conducted at home with the patient's parents. Construction of a timeline of events from birth to initial hospitalization indicated that the onset of illness had occurred just 38 h after birth, suggesting that the patient's exposure to C. baratii may have occurred at the birthing hospital in the immediate perinatal period.
Multiple environmental samples were collected from the patient's home and birthing hospital (Table 2) . Also, when the patient's correct diagnosis became known, fecal specimens were collected from both parents (a month after onset of the infant's illness) to evaluate the possibility of subclinical intestinal colonization. Despite an extensive laboratory effort, no C. baratii was isolated from the adult fecal or environmental specimens, including household vacuum cleaner dust, a known source of C. botulinum (1, 13, 15, 17, 18 ). The family car and pickup truck air filters, studied as a means of sampling airborne spores, were also negative. Parenthetically, C. botulinum type A was isolated from most of the soil sites sampled (which exemplifies the ubiquity of this organism) ( Table 2) .
Infant botulism is an acute, symmetric, descending, flaccid paralysis that occurs in infants younger than 12 months of age. The mean (median) age at onset for all California cases from 1976 to 2004 was 3.4 (3.1) months. Definitive laboratory diagnosis identifies Clostridium botulinum toxin and/or organisms in fecal specimens following intestinal colonization by swallowed C. botulinum spores (2). After absorption, botulinum toxin produced in the intestinal lumen binds to terminal motor neurons, where it prevents acetylcholine release and thereby causes flaccid paralysis (2) . Detection and identification of botulinum toxin is accomplished using the mouse neutralization bioassay (5) .
With the exception of rare dual-toxin-producing strains, most C. botulinum strains produce just one of the seven known botulinum toxin types designated A to G (4, 7, 11). Worldwide, reported infant botulism almost always results from C. botulinum strains that produce botulinum toxin type A or type B. However, four cases of infant botulism caused by neurotoxigenic C. butyricum type E have been reported from Italy (3, 6) . Also, C. baratii type F has caused four cases of infant botulism (Table 3) (8, 10, 11, 12, 19, 20, 21) . We now report laboratory, environmental, and epidemiological aspects of the fifth instance of infant botulism caused by neurotoxigenic C. baratii type F. Clinical particulars of this case are reported elsewhere (14) . This is the first such case to occur in California in our 29 years of laboratory surveillance and the youngest (age at onset of disease) infant botulism patient ever recorded.
Rare strains of C. botulinum that produce two toxins and the non-botulinum clostridia that produce botulinum toxin (i.e., C. butyricum type E and C. baratii type F), may be more prevalent than realized (4, 9) . The botulism diagnostic laboratory serves a critical role in identifying these seldom-reported strains (4, 9) . All previously reported U.S. cases of C. baratii type F infant botulism occurred in unusually young patients. We suggest that clinicians include infant botulism caused by C. baratii type F in their differential diagnosis if the infant's illness is characterized by the triad that includes the following: (i) rapid onset, (ii) severe paralysis. and (iii) young patient age. The case reported here is remarkable because it is the first recognition of C. baratii type F infant botulism in California, it describes the youngest known patient to have infant botulism caused by C. baratii type F, and it involves the youngest known patient ever to have had infant botulism.
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